Cancer Prev Res (Phila). 2011 Mar;4(3):303-6. doi: 10.1158/1940-6207.CAPR-11-0053.

Challenges related to developing serum-based biomarkers for early ovarian cancer detection.

Source

Clinical Genetics Branch,Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA.

Abstract

In this issue of the journal, Cramer and colleagues and Zhu and colleagues report carefully designed phase 3 assessments of candidate ovarian cancer screening biomarkers. The main conclusion is that CA-125 remains the "best of a bad lot"; the new candidates have fallen short of expectations. We review factors impeding the development of an effective ovarian cancer screening strategy, highlight the requirements related to validating proposed screening biomarkers, and emphasize the risks from premature clinical applications of unvalidated tests, all underscoring the need for new research strategies.

Comment on

Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. [Cancer Prev Res (Phila). 2011]
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, et al. Cancer Prev Res (Phila). 2011 Mar; 4(3):365-74.
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. [Cancer Prev Res (Phila). 2011]
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, et al. Cancer Prev Res (Phila). 2011 Mar; 4(3):375-83.

PMID:: 21372029; [PubMed - indexed for MEDLINE]
PMCID:: PMC3077065

Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Tumor Markers, Biological

Grant Support

Z01 CP010144-10/CP/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Click here to read article using PubReader

Related citations in PubMed

The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. [Cancer Prev Res (Phila). 2011]
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples.
Jacobs I, Menon U. Cancer Prev Res (Phila). 2011 Mar; 4(3):299-302.
Personalizing CA125 levels for ovarian cancer screening. [Cancer Prev Res (Phila). 2011]
Personalizing CA125 levels for ovarian cancer screening.
Dorigo O, Berek JS. Cancer Prev Res (Phila). 2011 Sep; 4(9):1356-9.
Review Protein biomarkers of ovarian cancer: the forest and the trees. [Future Oncol. 2012]
Review Protein biomarkers of ovarian cancer: the forest and the trees.
Nolen BM, Lokshin AE. Future Oncol. 2012 Jan; 8(1):55-71.
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. [PLoS One. 2011]
Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.
Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, et al. PLoS One. 2011; 6(12):e28141. Epub 2011 Dec 7.
Review Prognostic biomarkers in ovarian cancer. [Cancer Biomark. 2010]
Review Prognostic biomarkers in ovarian cancer.
Huang J, Hu W, Sood AK. Cancer Biomark. 2010-2011; 8(4-5):231-51.

See reviews... See all...

Cited by 5 PubMed Central articles

Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. [PLoS One. 2011]
Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers.
Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, Mansfield BC, Bertenshaw GP. PLoS One. 2011; 6(12):e29533. Epub 2011 Dec 21.
Why have protein biomarkers not reached the clinic? [Genome Med. 2011]
Why have protein biomarkers not reached the clinic?
Hanash SM. Genome Med. 2011 Oct 26; 3(10):66. Epub 2011 Oct 26.
Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. [PLoS One. 2011]
Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion.
McKenzie AJ, Campbell SL, Howe AK. PLoS One. 2011; 6(10):e26552. Epub 2011 Oct 19.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Challenges related to developing serum-based biomarkers for early ovarian cancer...
Challenges related to developing serum-based biomarkers for early ovarian cancer detection.
Cancer Prev Res (Phila). 2011 Mar ;4(3):303-6. doi: 10.1158/1940-6207.CAPR-11-0053.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: